Monday, September 14, 2026

How Rasmotinib and PHI-501 Could Revolutionize Cancer Treatment: Insights from Bio Europe Spring 2026

Pharos iBio showcases its cancer treatments at Bio Europe Spring 2026, seeking global partnerships for Rasmotinib and PHI-501.

Yazan on Facing Messi: What He Learned from the World Cup Experience

Yazan of FC Seoul shares his World Cup experience, praising Messi's skills and confidence while reflecting on Jordan's historic debut.

Act of War! Kim’s Nuclear Parade With Russia and China Is a Bold New Challenge To Washington

Kim Jong Un emphasized military evolution and national defense in a speech marking the Workers' Party's 80th anniversary, avoiding direct U.S. criticism.

Tag: Mounjaro

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

Unlocking the Future: How Genomic Testing Enhances GLP-1 Obesity Treatment for Asian Patients

NGeneBio is developing tests to identify which patients benefit from GLP-1 weight loss drugs like Wegovy and Mounjaro, assessing side effects.

Novo Nordisk vs Eli Lilly: Is Weight Loss Advertising Misleading?

Novo Nordisk sues Eli Lilly for misleading ads on obesity drugs, claiming false comparisons and seeking corrective action in court.

Teen Prescriptions for GLP-1 Obesity Drugs Surge in Korea, Raising Misuse Concerns

Surge in GLP-1 obesity treatment prescriptions among teens raises concerns over misuse and potential health risks.

Mounjaro prescriptions surge 12-fold in 8 months, surpassing 200,000 monthly for the first time

Mounjaro prescriptions surged over tenfold in eight months, raising concerns about access for patients with obesity amid rising cosmetic demand.

Why Are Weight-Loss Drugs So Much Pricier in South Korea?

South Korea faces high obesity treatment costs compared to China and Japan, with no insurance coverage, despite potential patent expirations.

Ozempic Maker Swaps CEO, Bets $2.2B on New Obesity Drug Fight

Novo Nordisk's leadership change aims to reclaim its obesity treatment market share amid competition from Eli Lilly's Mounjaro.

New Study: Mounjaro Helps Users Drop Over 50 Pounds

Eli Lilly's Mounjaro leads U.S. obesity drug market, outperforming semaglutide in weight loss efficacy and safety.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.